Scarica l'app Stockscreener
66.63
0.05%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.61
Aprire:
$66.75
Volume 24 ore:
48,634
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.25B
Reddito:
$55.23M
Utile/perdita netta:
$-164.08M
Rapporto P/E:
-9.7325
EPS:
-6.8461
Flusso di cassa netto:
$-208.68M
1 W Prestazione:
-1.38%
1M Prestazione:
-27.31%
6M Prestazione:
+1.45%
1 anno Prestazione:
+10,089%
Intervallo 1D:
$66.14
$67.38
Intervallo di 1 settimana:
$66.24
$69.85
Portata 52W:
$0.6319
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
66.63 | 2.25B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
435.77 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.16 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.88 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.40 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.19 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool
Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal
Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com Canada
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com
Nektar Therapeutics (NKTR) R&D chief sells shares to cover RSU tax - Stock Titan
Nektar Therapeutics (NKTR) CEO logs small 444-share tax-related stock sale - Stock Titan
Is Nektar Therapeutics’ (NKTR) New CFO Hire and Equity Program Reframing Its Capital-Market Strategy? - simplywall.st
Nektar Q1 earnings & revenues lag estimates, pipeline in focus - MSN
NKTR Stock Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom - simplywall.st
[144] NEKTAR THERAPEUTICS SEC Filing - Stock Titan
Why Nektar Therapeutics Stock Rocked it Today - MSN
Nektar Therapeutics stock (US6354171056): FDA update and pipeline focus - AD HOC NEWS
Patient Square Capital LP Acquires 210,000 Shares of Nektar Therapeutics in Q1 2026News and Statistics - IndexBox
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares - AOL.com
BVF Group (NKTR) reports up to 2.85M shares—9.8% aggregate holding - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛
Nektar Therapeutics stock (US6354171056): $400M capital raise fuels Phase 3 autoimmune pipeline - AD HOC NEWS
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery - simplywall.st
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - Yahoo Finance
Nektar Therapeutics Raises $374 Million After Alopecia Data Release; AnaptysBio’s First Tracks Bio Debuts on NASDAQ - geneonline.com
Why Nektar Therapeutics Shares Are Sliding Now - TipRanks
Nektar Therapeutics adds to its 129% two-month run with alopecia news - MSN
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153 - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Pretty Bullish On The Stock After Recent Results - 富途牛牛
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $134 to $185 - Moomoo
Nektar posts 52-week data from mid-stage trial for hair loss therapy - msn.com
Nektar Therapeutics Enters Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright – 8-K Filing Details 27 - Minichart
Nektar Therapeutics Charts Aggressive Path With REZPEG - TipRanks
Nektar Therapeutics Names Rubinstein New Interim CFO - Moomoo
Nektar Therapeutics Establishes New Equity Distribution Agreement - TipRanks
Nektar Therapeutics announces $150 million equity distribution agreement and CFO transition - Investing.com Australia
Nektar Therapeutics announces $150 million equity distribution agreement and CFO transition By Investing.com - Investing.com South Africa
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | President & CEO |
May 19 '26 |
Sale |
65.51 |
444 |
29,086 |
75,045 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):